Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These topline results show early potential for the drug …